El interés en corto de Holley da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Holley. Los datos de interés en corto se actualizan cada dos semanas.

Holley (NYSE:HLLY) Bolsa, Informe de interés en corto

Holley

Holley Inc is a designer, marketer, and manufacturer of high-performance automotive aftermarket products, featuring a portfolio of iconic brands serving the car and truck industry. It offers a diversified line of performance automotive products including fuel injection systems, tuners, exhaust products, carburetors, safety equipment and various other performance automotive products. The Company's products are designed to enhance street, off-road, recreational and competitive vehicle performance through increased horsepower, torque and drivability. The company's brands include Holley, APR, MSD and Flowmaster, among others. It derives revenue from the U.S. and Italy, of which prime revenue is derived from the U.S.

Holley Inc

Rosenblatt analyst Kevin Cassidy upgrades Innoviz Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVZ#NASDAQ">INVZ</a>) from Neutral to Buy and raises the price target from $3.25 to $4.

News

Upgrades

Price Target

Analyst Ratings

INVZ

Rosenblatt Upgrades Innoviz Technologies to Buy, Raises Price Target to $4

<a href="https://www.globenewswire.com/Tracker?data=Myv-69gOUCJgo4iWs3nsz31ZPczO7ocKKHfzl4XL1e1L9RkdUKQibBVRmpixUEREcIgnv9SO7KnFXgpTtMfCRw==">Silvaco Group, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>), a provider of TCAD, EDA software and SIP solutions that enable semiconductor design and digital twin modeling through AI software and innovation, today announced a strategic sales partnership with <a href="https://www.globenewswire.com/Tracker?data=r59takPzEK4CVfOOZ6LI-kaTEo9oZxfJ2pa2N0-vWDB0w4FefKTfo_XE83yqW-CLiVzP2weInfF_itKp1KGV4WZvgklawtOGvXVXUZHsjUQ=">Micon Global.</a> The partnership between&nbsp;Silvaco&nbsp;and&nbsp;Micon Global&nbsp;is expected to drive&nbsp;Silvaco's expansion across the EMEA market, leveraging&nbsp;Micon Global's expertise to enhance client access to&nbsp;Silvaco's design solutions.

SVCO

Silvaco Partners With Micon Global to Boost Semiconductor Solutions in EMEA

"We have already taken steps to address all concerns raised by the CMA after their Phase 1 investigation. For example, Synopsys previously announced plans to sell its Optical Solutions business to Keysight, subject to the closing of Synopsys' proposed acquisition of Ansys," the company said.

ANSS

SNPS

Synopsys Responds To UK CMA's Phase 1 Announcement Regarding Ansys Acquisition; Continues To Express Support For The Transaction

CCC Intelligent Solutions Holdings Inc. (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCS#NASDAQ">CCCS</a>), a leading cloud platform provider for the P&amp;C insurance economy, today announced that its board of directors has approved a new share repurchase authorization to repurchase up to $300 million of the Company's outstanding common stock.
Under the repurchase authorization, the Company is authorized to repurchase shares through open market purchases, privately negotiated transactions, or accelerated share repurchases. The repurchase authorization does not obligate the Company to repurchase shares and the specific timing and amount of repurchases may vary based on available capital resources, market conditions, management's discretion, securities law limitations, and other factors. Repurchases, if any, will be funded out of available liquidity and free cash flow.

Buybacks

CCCS

CCC Intelligent Solutions Board Approved Fresh $300M Share Buyback

Winnebago Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $0.20 by 115 percent. The company reported quarterly sales of $625.600 million which missed the analyst consensus estimate of $672.232 million by 6.94 percent. This is a 18.01 percent decrease over sales of $763.000 million the same period last year.

Earnings

Earnings Misses

Winnebago Industries Q1 2025 Adj. EPS $(0.03) Misses $0.20 Estimate, Sales $625.600M Miss $672.232M Estimate

ECARX Holdings Plans Repurchase Of Up To $20M Of Its Ordinary Shares Until  Close Of Business On September 30, 2025

Management

APLT

Applied Therapeutics Names John H. Johnson As Executive Chairman; Shoshana Shendelman Has Stepped Down As Chair And CEO; Les Funtleyder Named As Interim CEO

Chardan Capital analyst Rudy Li initiates coverage on Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Buy rating and announces Price Target of $40.

Initiation

PRTA

Chardan Capital Initiates Coverage On Prothena Corp with Buy Rating, Announces Price Target of $40

Across the recent three months, 5 analysts have shared their insights on Evercore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVR#NYSE">EVR</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $307.2, a high estimate of $339.00, and a low estimate of $265.00. This current average has increased by 12.2% from the previous average price target of $273.80. 
<img src="https://www.benzinga.com/files/images/story/2024/1734696055_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Evercore by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$339.00</td>
<td>$269.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$318.00</td>
<td>$266.00</td>
</tr>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$308.00</td>
<td>$306.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$265.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$306.00</td>
<td>$273.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Evercore. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Evercore compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Evercore's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Evercore's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EVR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Evercore analyst ratings.</a>
<h2>All You Need to Know About Evercore</h2>
Evercore is an independent investment bank that derives the majority of its revenue from financial advisory, including merger, acquisition, and restructuring advisory. It also has institutional equities trading, equity underwriting, and investment management businesses that account for around 20% of net revenue. The company was founded in 1996 and went public in 2006. Evercore had approximately 2,200 employees at the end of 2023, and about 75% of its revenue is derived from the United States.
<h3>Evercore: Delving into Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Evercore's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 28.76%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 10.68%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Evercore's ROE stands out, surpassing industry averages. With an impressive ROE of 5.1%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Evercore's ROA excels beyond industry benchmarks, reaching 2.28%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.55, Evercore adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Evercore: 5 Analysts Share Their Views

Throughout the last three months, 8 analysts have evaluated Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Avidity Biosciences, revealing an average target of $65.75, a high estimate of $78.00, and a low estimate of $59.00. Witnessing a positive shift, the current average has risen by 9.22% from the previous average price target of $60.20.
<img src="https://www.benzinga.com/files/images/story/2024/1734696047_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive Avidity Biosciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$72.00</td>
<td>-</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$67.00</td>
<td>-</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$78.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Corinne Johnson</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$59.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Avidity Biosciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Avidity Biosciences compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Avidity Biosciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Avidity Biosciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/RNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Avidity Biosciences analyst ratings.</a>
<h2>About Avidity Biosciences</h2>
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
<h3>Financial Milestones: Avidity Biosciences's Journey</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Decline in Revenue: Over the 3 months period, Avidity Biosciences faced challenges, resulting in a decline of approximately -17.1% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Avidity Biosciences's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -3441.7%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Avidity Biosciences's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -5.9%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Avidity Biosciences's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -5.38%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.01, Avidity Biosciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 8 Analyst Ratings Have To Say About Avidity Biosciences

In the preceding three months, 16 analysts have released ratings for Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">14</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Dollar Tree and provided 12-month price targets. The average target is $78.81, accompanied by a high estimate of $100.00 and a low estimate of $65.00. Experiencing a 0.78% decline, the current average is now lower than the previous average price target of $79.43. 
<img src="https://www.benzinga.com/files/images/story/2024/1734696039_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Dollar Tree among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>John Heinbockel</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Hold</td>
<td>$75.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$70.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$83.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$76.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$72.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Daniel Binder</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$92.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$65.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$82.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$75.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$100.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Brandon Fletcher</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$76.00</td>
<td>-</td>
</tr>
<tr>
<td>Karen Short</td>
<td>Melius Research</td>
<td>Announces</td>
<td>Hold</td>
<td>$70.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dollar Tree. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dollar Tree compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Dollar Tree's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Dollar Tree's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DLTR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Dollar Tree analyst ratings.</a>
<h2>Get to Know Dollar Tree Better</h2>
Dollar Tree operates discount stores across the United States and Canada, with over 8,600 shops under its namesake banner and nearly 7,800 under Family Dollar. About 47% of Dollar Tree's sales in fiscal 2023 were composed of consumables (including food, health and beauty, and cleaning products), around 45% from variety items (including toys and homewares), and over 5% from seasonal items. The Dollar Tree banner sells most of its merchandise at the $1.25 price point and positions its stores in well-populated suburban markets. Conversely, Family Dollar primarily sells consumable merchandise (80% of the banner's sales) at prices below $10. About two-thirds of Family Dollar's stores are located in urban and suburban markets, with the remaining one-third located in rural areas.
<h3>Key Indicators: Dollar Tree's Financial Health</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Dollar Tree's remarkable performance in 3 months is evident. As of 31 October, 2024, the company achieved an impressive revenue growth rate of 3.46%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 3.08%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Dollar Tree's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.11%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Dollar Tree's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.02%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.38.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DLTR

A Glimpse Into The Expert Outlook On Dollar Tree Through 16 Analysts

In the last three months, 12 analysts have published ratings on Tradeweb Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TW#NASDAQ">TW</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $141.75, a high estimate of $153.00, and a low estimate of $127.00. Marking an increase of 6.72%, the current average surpasses the previous average price target of $132.82. 
<img src="https://www.benzinga.com/files/images/story/2024/1734696029_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Tradeweb Markets. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$153.00</td>
<td>$149.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$131.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$149.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$151.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$146.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$127.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$147.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Patrick O'Shaughnessy</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$133.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Michael Carrier</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$139.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$136.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Buy</td>
<td>$139.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Tradeweb Markets. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Tradeweb Markets compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Tradeweb Markets's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Tradeweb Markets's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TW/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tradeweb Markets analyst ratings.</a>
<h2>Unveiling the Story Behind Tradeweb Markets</h2>
Founded in 1998 and headquartered in New York City, Tradeweb Markets is a leading fixed-income trading platform. While it does offer electronic processing for some voice-negotiated trades, the company focuses primarily on providing electronic trading networks that connect broker/dealers, institutional clients, and retail customers. While the company offers trading in a wide variety of products, the bulk of its business is in U.S. and European government debt, mortgage-backed securities, interest-rate swaps, and U.S. and international corporate bonds. The firm also sells fixed-income trading and price data, primarily through a deal with Refinitiv's Eikon service.
<h3>Key Indicators: Tradeweb Markets's Financial Health</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Tradeweb Markets's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 36.72% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Tradeweb Markets's net margin is impressive, surpassing industry averages. With a net margin of 25.36%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Tradeweb Markets's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.01%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Tradeweb Markets's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.56%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Tradeweb Markets's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Tradeweb Markets Stock: Analyst Perspectives (12 Ratings)

During the last three months, 4 analysts shared their evaluations of Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $5.5, a high estimate of $7.00, and a low estimate of $5.00. Highlighting a 8.33% decrease, the current average has fallen from the previous average price target of $6.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1734696021_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Spero Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Josh Schimmer</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>In-Line</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$5.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Spero Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Spero Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Spero Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Spero Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SPRO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Spero Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Spero Therapeutics's Background</h2>
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
<h3>Spero Therapeutics: Financial Performance Dissected</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Challenges: Spero Therapeutics's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -66.56%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Spero Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -219.3%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Spero Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -23.49%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -12.03%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.07, Spero Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SPRO

What 4 Analyst Ratings Have To Say About Spero Therapeutics

With the holiday spirit in full swing, many investors are looking to capitalize on potential opportunities in cryptocurrencies, and thanks to the 24&#215;7 nature of the asset class, the gains and losses aren&#8217;t confined to normal trading windows.
Optimism has been running high lately with Bitcoin's <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42336184/exclusive-bitcoin-crossing-100000-is-a-defining-moment-experts-say">historic climb above $100,000</a> and anticipated further gains if President-elect Donald Trump&#8217;s planned <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42554929/donald-trump-reportedly-discussed-bitcoin-reserve-in-meeting-with-cryptocom-ceo-kris-marszalek">strategic Bitcoin reserve</a> becomes a reality once he enters office.
Bitcoin's bullish run has rubbed off on the broader market, with the total cryptocurrency market capitalization increasing by 8% over the month, <a href="https://coinmarketcap.com/charts/">according </a>to CoinMarketCap.
However, the sheer value of blue-chip currencies like Bitcoin could unnerve an average trader. Even fractional units could cost a bomb for people who do not intend to invest heavily.
In light of these developments, we look at some pocket-friendly cryptocurrencies that could experience upsides this Christmas and deserve a space in your bag.
<h3 class="wp-block-heading">ENA</h3>
Ethena Labs (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ENA</a>) has attracted significant attention lately after the Trump-backed cryptocurrency project, World Liberty Financial, went on a buying spree.
The platform has <a href="https://platform.spotonchain.ai/en/entity/2361">bought </a>nearly $670 million of ENA tokens for its decentralized finance activities and also<a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42568122/trump-backed-world"> announced a partnership</a> with Ethena Labs.
Large investors seemed to have taken a liking to these developments. In the past three days, a whale accumulated over $13 million worth of ENA, according to on-chain data.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Whales are accumulating <a href="https://twitter.com/search?q=%24ENA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ENA</a>. Over the past 3 days, this newly created wallet has withdrawn 13.65M <a href="https://twitter.com/search?q=%24ENA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ENA</a>($13.42M) from <a href="https://twitter.com/hashtag/Binance?src=hash&amp;ref_src=twsrc%5Etfw">#Binance</a>.<a href="https://t.co/yVzvPAUlYG">https://t.co/yVzvPAUlYG</a> <a href="https://t.co/warF4CflA8">pic.twitter.com/warF4CflA8</a>
&mdash; Lookonchain (@lookonchain) <a href="https://twitter.com/lookonchain/status/1869965507417514422?ref_src=twsrc%5Etfw">December 20, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Additionally, sentiment around the coin was strong on social media, with positive mentions jumping to 91%, according to TradingView.
Price Action: The coin was valued at $0.8873 as of this writing, 41% below its all-time high of $0.8873.
<h3 class="wp-block-heading">LINK</h3>
Like ENA, Chainlink (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/link/usd">LINK</a>) has also benefitted from World Liberty Financial purchases. The Trump-linked platform has accumulated nearly $1.75 million in LINK tokens as of this writing.
Additionally, a <a href="https://www.benzinga.com/24/12/42608825/shytoshi-kusama-says-huge-news-as-shiba-inu-partners-with-chainlink-to-boost-shibarium-ecosystem-tokens">new partnership</a> with the Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) ecosystem has boosted the spirits of LINK holders.
LINK has surged more than 46% this year. Its network value-to-transaction ratio, analogous to the price-to-earnings ratio for stocks, was around 25. The lower value indicated that it was undervalued, potentially paving the way for market value growth.
Price Action: The coin was valued at $22.32 as of this writing, 57% below its all-time high of $52.70.
See Also:<a href="https://www.benzinga.com/24/12/42519107/if-you-invested-1000-in-bitcoin-when-the-first-bitcoin-etf-was-filed-heres-how-much-youd-have-today"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42560698/microstrategys-aggressive-bitcoin-strategy-raises-eyebrows-in-crypto-community">MicroStrategy&#8217;s Aggressive Bitcoin Strategy Raises Eyebrows In Crypto Community</a>
<h3 class="wp-block-heading">Pudgy Penguins</h3>
Bored? Don't worry, we have some meme coin action for you.
The <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42562051/pudgy-penguins-pengu-token-extends-rally-outperforms-dogecoin-shiba-inu-on-wednesday">newly launched coin</a> of the famous Pudgy Penguin (PENGU) brand has made heads turn, skyrocketing 434% in a week that saw the broader market crack heavily.
In less than a week since launch, PENGU has skyrocketed to a $1 billion market valuation, becoming the sixth-largest meme coin.
Price Action: The coin was valued at $0.02618 as of this writing.
<h3 class="wp-block-heading">XRP</h3>
It's time for some A-listers! Payment-focused cryptocurrency XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) has been given a new lease of life after Trump's victory.
The coin has been the best-performing altcoin since the election day, more than quadrupling in value.&nbsp;
With SEC Chair Gary Gensler's tenure coming to an end and cryptocurrency-friendly Paul Atkins set to <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42323248/trump-nominates-paul-atkins-as-sec-chair-emphasizing-digital-assets-as-key-to-making-america-greater">succeed</a> him , investors feel more confident about XRP, the coin that bore the <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40240559/xrp-outshines-bitcoin-ethereum-to-become-biggest-daily-gainer-after-judge-imposes-125m-pen">brunt of regulatory pressures</a> in the last few years.
Moving averages flashed a ‘Buy' signal for XRP while positive social mentions increased to 81%.
Furthermore, whales have been piling XRP in recent days, reflecting a bullish sentiment.
Price Action: The coin was valued at $2.22 as of this writing, 34.4% below its all-time high of $3.40.
<h3 class="wp-block-heading">Bitcoin SV</h3>
While Bitcoin can be an expensive buy, how about its cheaper play?
Bitcoin SV (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BSV</a>), a Bitcoin hard fork, has been seen reacting <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40700041/bitcoins-low-cost-offshoot-bsv-becomes-markets-biggest-gainer-while-king-crypto-plunges-ov">euphorically</a> to the leading cryptocurrency's upward moves. In fact, <a href="https://www.benzinga.com/news/24/12/42348260/bitcoin-sv-is-up-80-over-the-past-month-whats-going-on">BSV hit its highest value since mid-April</a> when Bitcoin hit $100,000.
Price Action: Its current price was $50, orders of magnitude less than Bitcoin&#8217;s. This might make it a suitable purchase for people wishing to gain exposure to the top cryptocurrency&#8217;s movements without burning a hole in their pocket.
Benzinga also reached out to Dan Polotsky, founder of leading Bitcoin ATM operator CoinFlip, who revealed coins he was personally excited about.
"I can't predict what will happen this Christmas; however, I do love frog-based Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>),&nbsp; dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>), Bonk (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BONK</a>), and Popcat (POPCAT)," Polotsky said.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42545656/bitcoin-is-no-manhattan-real-estate-peter-schiff-challenges-microstrategys-micheal-saylor-btc-doesnt-generate-any-income">Bitcoin Is No Manhattan Real Estate, Peter Schiff Challenges MicroStrategy&#8217;s Michael Saylor: &#8216;BTC Doesn&#8217;t Generate Any Income&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BONK

$BSV

$ENA

$LINK

$PEPE

$SHIB

$WIF

$XRP

Have Risk Appetite? Here Are 5 Cryptos That Could Make Your Christmas Merry

Claims of Wall Street dominance in the housing market vastly overstate institutional buyers&#8217; actual market share, with data showing large investors account for less than 1% of recent purchases, according to a new analysis from HousingWire.
The viral claim that institutional investors purchased 44% of American homes in 2023 proves mathematically impossible based on market data. According to Freddie Mac data cited by HousingWire, even at their peak, institutional buyers – defined as those purchasing 100+ homes annually – never exceeded 2.5% market share since 2000.
Don't Miss:
<ul>
<li>CEO of Integris gathered a team of senior investment managers who have $34.22 billion in combined owned and managed assets in the West Coast —<a href="https://www.benzinga.com/money/integris"> here&#8217;s how to invest in their private credit fund that targets 12% annual interest rate.</a></li>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://arrivedhomes.go2cloud.org/aff_c?offer_id=15&amp;aff_id=1006&amp;aff_sub=yahoo&amp;aff_sub2=byerscta100">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
</ul>
While overall investor activity has grown to roughly 30% of purchases, the vast majority comes from small-scale buyers acquiring between one and nine properties. Large institutional buyers with portfolios exceeding 1,000 properties represented just 0.4% of the market share in Q2 2023.
Recent mortgage application trends further contradict the Wall Street takeover narrative. Growing mortgage demand indicates increased activity from traditional homebuyers, as institutional investors typically make all-cash purchases. Each rate dip toward 6% has triggered surges in mortgage applications from primary residence buyers.
The misconception gained traction through social media and even prompted legislative response, with Democratic lawmakers proposing restrictions on hedge fund purchases of single-family homes.&nbsp;
See Also: During market downturns, investors are learning that unlike equities, these<a href="https://www.benzinga.com/money/connect-invest-real-estate-notes-y2"> high-yield real estate notes that pay 7.5% &#8211; 9% are protected by resilient assets, buffering against losses. </a>However, market data consistently shows individual buyers, not Wall Street firms, drive housing demand.
Generational shifts explain more of the market&#8217;s dynamics than institutional activity. Millennials dominated purchases from 2013 until 2022&#8217;s rate increases, when Gen X and Baby Boomer buyers regained market share leadership, according to National Association of Realtors data cited in the report.
The current near-record low housing inventory stems from broader market forces rather than institutional hoarding. Even companies frequently cited in the Wall Street narrative, like BlackRock and Blackstone, maintain relatively small residential portfolios compared to the overall housing stock.
Trending: Unlock the hidden potential of commercial real estate —<a href="https://equitymultiple.com/benzinga?invite=benzinga&amp;utm_campaign=product-promotion-earn&amp;utm_source=yahooFinance&amp;utm_medium=affiliate&amp;utm_content=unlockboost-yahoo"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today! </a>The investment patterns align with local market realities rather than coordinated institutional strategy. John Burns Real Estate data cited by HousingWire shows mom-and-pop investors typically concentrate on properties requiring renovation or offering steady rental income in growing communities. At the same time, <a href="https://www.benzinga.com/markets/24/12/42499977/wall-street-pours-billions-into-build-to-rent-communities-betting-big-against-home-ownership-amid-high-prices-and-interest-rates">institutional buyers focus primarily on newly constructed homes in select markets</a>.
The data demonstrates a disconnect between viral social media claims and market reality. While <a href="https://www.benzinga.com/opinion/24/07/39602191/private-equity-firms-are-buying-up-real-estate-in-these-areas">investor participation in housing has increased over two decades</a>, individual buyers acquiring a handful of properties – not Wall Street institutions – account for most of that growth.
<h2 class="wp-block-heading">You Can Profit From Real Estate Without Being A Landlord</h2>
Real estate is a great way to diversify your portfolio and earn high returns, but it can also be a big hassle. Luckily, there are other ways to tap into the power of real estate without owning property. <a href="https://www.benzinga.com/go/arrived-private-credit-yf">Arrived Home's Private Credit Fund&#8217;s has historically paid an annualized dividend yield of 8.1%&#x2A;</a>, which provides access to a pool of short-term loans backed by residential real estate. The best part? Unlike other private credit funds, <a href="https://www.benzinga.com/go/arrived-private-credit-yf">this one has a minimum investment of only $100.&nbsp;</a>
Looking for fractional real estate investment opportunities? The <a href="https://www.benzinga.com/alternative-investments/real-estate">Benzinga Real Estate Screener</a> features the latest offerings.

Real Estate

Is Wall Street Really Buying 44% Of Homes? Report Says Not Even Close

Keefe, Bruyette &amp; Woods analyst Aidan Hall upgrades Moelis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MC#NYSE">MC</a>) from Market Perform to Outperform and raises the price target from $71 to $86.

Keefe, Bruyette & Woods Upgrades Moelis to Outperform, Raises Price Target to $86

Ratings for Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) were provided by 14 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">12</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $67.36, a high estimate of $80.00, and a low estimate of $52.00. This upward trend is evident, with the current average reflecting a 6.5% increase from the previous average price target of $63.25.
<img src="https://www.benzinga.com/files/images/story/2024/1734696012_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Rhythm Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$76.00</td>
<td>-</td>
</tr>
<tr>
<td>Corinne Jenkins</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$66.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$69.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$69.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$69.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Phil Nadeau</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$64.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Rhythm Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Rhythm Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Rhythm Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Rhythm Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RYTM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Rhythm Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Rhythm Pharmaceuticals Better</h2>
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
<h3>Unraveling the Financial Story of Rhythm Pharmaceuticals</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining Rhythm Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 47.76% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Rhythm Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -131.25%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Rhythm Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -172.64%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Rhythm Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -11.71%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Rhythm Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.36, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RYTM

Forecasting The Future: 14 Analyst Projections For Rhythm Pharmaceuticals

HC Wainwright &amp; Co. analyst Andrew Fein maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Buy and lowers the price target from $600 to $535.

VRTX

HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Lowers Price Target to $535

On Friday, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) stock plunged after the company released headline results from the REDEFINE 1 Phase 3 trial in the <a href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=915082" target="_blank" rel="noreferrer noopener">global REDEFINE program</a>.
REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual components cagrilintide 2.4 mg, semaglutide 2.4 mg, and placebo, all administered once-weekly.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42467660/novo-nordisks-ozempic-label-expansion-snags-approval-from-european-drug-regulators-advisory-panel" rel="noreferrer noopener">Novo Nordisk&#8217;s Ozempic Label Expansion Snags Approval From European Drug Regulator&#8217;s Advisory Panel</a>
The <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=915082" rel="noreferrer noopener">trial</a> included 3,417 randomized people with obesity or overweight with one or more comorbidities and a mean baseline body weight of 106.9 kg.
The trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss with CagriSema versus placebo at week 68.
When evaluating the effects of treatment if all people adhered to treatment, people treated with CagriSema achieved a weight loss of 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and 2.3% with placebo alone.
In November, Novo Nordisk said its hybrid drug, CagriSema, aims to reduce weight by 25% without <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41706292/as-race-to-best-miracle-obesity-drug-heats-up-ozempic-maker-novo-nordisk-tests-new-hybrid-drug-th" rel="noreferrer noopener">added side effects</a>.
In addition, 40.4% of patients who received CagriSema reached a weight loss of 25% or more after 68 weeks, compared to 6.0% with cagrilintide 2.4 mg, 16.2% with semaglutide 2.4 mg, and 0.9% with placebo.
When applying the treatment policy estimand, people treated with CagriSema achieved a weight loss of 20.4% compared to a reduction of 11.5% with cagrilintide 2.4 mg, 14.9% with semaglutide 2.4 mg and 3.0% with placebo.
In the trial, CagriSema, cagrilintide 2.4 mg and semaglutide 2.4 mg appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema were gastrointestinal, and the vast majority were mild to moderate and diminished over time, consistent with the GLP-1 receptor agonist class.
The results from the second pivotal phase 3 trial, REDEFINE 2, in adults with type 2 diabetes and either obesity or overweight are expected during the first half of 2025.
In reaction to lower-than-expected trial data, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) stock is trading higher. Lilly&#8217;s own obesity injection containing tirzepatide demonstrated sustained average weight loss of 22.9% (15 mg dose) through the three-year treatment <a target="_blank" href="https://www.benzinga.com/24/11/41985752/eli-lillys-detailed-phase-3-trial-data-show-99-of-patients-on-popular-mounjarozepbound-remained-diabetes-free-for-even-at-three-years" rel="noreferrer noopener">period for the efficacy estimandi</a>.&nbsp;
Recently, Novo Nordisk stock came under pressure when two new studies from the University of Southern Denmark suggested that Ozempic, a diabetes medication, may increase the risk of developing a <a target="_blank" href="https://www.benzinga.com/24/12/42557565/ozempic-maker-novo-nordisks-poised-to-go-under-european-review-for-potential-increased-risk-of-rare-eye-disease" rel="noreferrer noopener">rare eye condition</a>.
Price Action: NVO stock is down 16.50% at $86.33, and LLY stock is up 8.91% at $825 during the premarket session at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42600472/your-healthcare-costs-are-soaring-us-spending-reached-5-trillion-in-2023-with-major-increase-in-obesity-and-diabetes-drugs-hospital-services" target="_blank" rel="noreferrer noopener">Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

Movers

Trading Ideas

General

Novo Nordisk's Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges

IIPR

Innovative Industrial Properties Reports Default By Pharmacann On Its Obligations To Pay Rent For The Month Of December Under Six Of The Eleven Leases, For Properties Located In Illinois, Massachusetts, Michigan, New York, Ohio And Pennsylvania

Sees Q4 adjusted EBITDA $24M-$29M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

Holley sees Q4 revenue $133M-$143M, consensus $154.3M

Holley Inc. 2024 Q3 - Results - Earnings Call Presentation

Holley Inc. ( ($HLLY) ) has released its Q3 earnings. Here is a breakdown of the information Holley Inc. presented to its investors. Holley Perform...

Holley Inc. Reports Q3 2024 Earnings Amid Strategic Shifts

Companies in the Consumer Cyclical sector have received a lot of coverage today as analysts weigh in on Holley (HLLY – Research Report), Playags (A...

Analysts Have Conflicting Sentiments on These Consumer Cyclical Companies: Holley (HLLY), Playags (AGS) and OneSpaWorld Holdings (OSW)

Telsey Advisory lowered the firm's price target on Holley (HLLY) to $4.50 from $5.50 and keeps an Outperform rating on the shares. While the compan...

Holley price target lowered to $4.50 from $5.50 at Telsey Advisory

In a report released yesterday, Brian McNamara from Canaccord Genuity maintained a Buy rating on Holley (HLLY – Research Report), with a price targ...

Holley Inc.: Buy Rating Reaffirmed Despite Q3 Underperformance, Highlighting Long-Term Growth Potential

Holley (HLLY) reported strong financial results for the third quarter. With the solid demand for its product offerings, innovative offerings, and expanding industry-wide footprint, the company is poised for continued growth. So, let's determine whether Holley is an ideal addition to your portfolio. Read more to find out... Holley Inc. (<a href="https://stocknews.com/stock/HLLY/">HLLY</a>) operates as a designer, manufacturer, and marketer of automotive aftermarket products for car and truck enthusiasts internationally. The company's products span various automotive platforms and sell across multiple channels. In the recently reported quarter, the company posted net sales of $134.04 million, and its adjusted gross profit was $52.31 million.
Recently, the company expanded its presence at the annual Specialty Equipment Market Association (SEMA) show with a larger showcase space, demonstrating its global leadership in the automotive performance aftermarket. With its portfolio of over 70 top brands, HLLY's SEMA booth featured innovative and cutting-edge platform solutions designed for automotive enthusiasts.
During the third quarter, Holley expanded its innovative product portfolio through brands like Baer Brakes and Simpson. Baer Brakes released Baer BIG Claw Performance Brake Kits and Baer Claw Rotors, which improve the vehicle's stopping power and elevate the overall style, look, and feel. Also, Simpson launched its Devil Ray 3.0 and Desert Devil 3.0 racing and off-road helmets.
These innovations continue reinstating Holley's position in the high-performance automotive aftermarket industry, widening its product offerings and market share. Also, in the last reported quarter, the company achieved growth in significant areas of the business and financial operations, including a 16% year-over-year increase in its direct-to-consumer channel through its well-executed marketing calendar.
Matthew Stevenson, President and CEO of Holley, commented, "We continued our progress in our organizational transformation through the third quarter and are encouraged by the immediate impact that our new team members have made in their short time here. Of note, digital modernization and customer service optimization, B2B sales capabilities, new and targeted product launches, and revamped pricing strategy have all been upgraded within the last year and are well positioned to drive our organic growth engine."
According to the fiscal 2024 fourth-quarter outlook, HLLY expects net sales between $133 million and $143 million. The company's adjusted EBITDA is expected to range from $24 million to $29 million.
For the full fiscal year, the company has its net sales guidance between $595 million and $605 million. Its adjusted EBITDA is expected to be $115 million - $120 million.
Shares of HLLY have surged 1.5% over the past month to close its last trading session at $2.76.
Let's look at factors that could influence HLLY's performance in the upcoming months.
Positive Recent Development
On October 15, HLLY's Flowmaster launched the Flowmaster Signature Series, the brand's new premium exhaust line. It is engineered for increased power and performance. The next-generation exhaust system provides a finely tuned sound and features brushed stainless steel for a clean, high-end look that resists premature rusting.
The Flowmaster Signature Series reflects HLLY's commitment to delivering performance, safety, fun, and excitement to automotive enthusiasts. It is made of top-line materials and delivers significant gains in power and torque over stock exhaust systems. The Signature Series also features a unique, user-friendly design, allowing simple at-home installation.
Also, on September 26, HLLY's Baer Brakes launched Baer BIG Claw Performance Brake Kits and Baer Claw Rotors. They are designed for modern truck enthusiasts to improve a vehicle's stopping power and elevate the overall style, look, and feel. Popular vehicle fitments for the new Baer products include the Ford F-150, Ford Bronco, Ram Trucks, Jeep JL/JT, Chevrolet Silverado 1500, and Chevrolet Suburban.
Robust Financials
HLLY reported net sales of $462.17 million during the nine months that ended September 29, 2024, and its adjusted gross profit was $183.49 million. The company's <a href="https://www.investopedia.com/terms/a/adjusted-ebitda.asp">adjusted EBITDA</a> came in at $118.71 million for the period.
In addition, the company's adjusted net income came in at $12.25 million and $0.10 per share for the period, respectively. Also, its free cash flow was $40.05 million.
Furthermore, the company's cash and cash equivalents stood at $50.75 million as of September 30, 2024, compared to $41.08 million as of December 31, 2023.
Low Valuation
In terms of forward EV/EBITDA, HLLY is currently trading at 7.48x, 28.7% lower than the industry average of 10.49x. The stock's forward P/E of 19.71x is considerably lower than the industry average of 19.83x.
Additionally, the stock's forward EV/EBIT and Price/Sales of 13.77x and 0.53x are 14% and 46.3% lower than the industry averages of 16.01x and 1x, respectively.
Favorable Analyst Estimates
Analysts expect HLLY's revenue for the second quarter (ending June 2025) to increase 3.5% year-over-year to $175.37 million. The consensus EPS estimate of $0.12 for the same quarter indicates a 15.7% year-over-year improvement.
For the fiscal year ending December 2025, the company's revenue and EPS are expected to grow 4.1% and 170.4% year-over-year to $631.79 million and $0.30, respectively.
High Profitability
HLLY's trailing-12-month EBIT margin of 11.62% is 42.1% higher than the industry average of 8.17%. Its trailing 12-month gross profit margin of 38.02% is higher than the industry average of 37.57%. Similarly, its trailing 12-month levered FCF margin of 11.85% is 144.6% higher than the industry average of 4.84%.
POWR Ratings Reflect Promise
HLLY's solid fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, translating to a Buy in our proprietary system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. HLLY has a B grade for Value, which is in sync with the company's lower valuation.
In addition, the stock has a B grade for Quality, consistent with its higher-than-industry profitability.
HLLY is ranked #6 in the 60-stock B-rated <a href="https://stocknews.com/category/auto-parts/">Auto Parts</a> industry.
Beyond what I have stated above, we have also given HLLY grades for Sentiment, Growth, Momentum, and Stability. Get access to all the HLLY Ratings <a href="https://stocknews.com/stock/HLLY/">here</a>.
Bottom Line
HLLY is a leading automotive aftermarket products manufacturer and provider. The company recently reported solid earnings for the third quarter of fiscal 2024. The company's strong industry footing, strategic initiatives, expanding product portfolio, and solid financial performance position it for bright long-term prospects. So, this stock could be an ideal buy now.
How Does Holley Inc. (HLLY) Stack Up Against Its Peers?
While HLLY has an overall POWR Rating of B, investors could also check out these other stocks within the B-rated <a href="https://stocknews.com/category/auto-parts/">Auto Parts</a> industry with A (Strong Buy) or B (Buy) ratings:
Ituran Location &amp; Control Ltd. (<a href="https://stocknews.com/stock/ITRN/">ITRN</a>)
Allison Transmission Holdings, Inc. (<a href="https://stocknews.com/stock/ALSN/">ALSN</a>)
Compagnie Generale des Etablissements Michelin ADR (<a href="https://stocknews.com/stock/MGDDY/">MGDDY</a>).
For exploring more A and B-rated auto parts stocks, <a href="https://stocknews.com/category/auto-parts/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
HLLY shares were trading at $2.78 per share on Monday afternoon, up $0.02 (+0.72%). Year-to-date, HLLY has declined -42.92%, versus a 26.92% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/hlly-itrn-alsn-mgddy-is-holleys-dominance-in-automotive-aftermarket-a-buy-signal/>Is Holley's Dominance in Automotive Aftermarket a Buy Signal?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Is Holley's Dominance in Automotive Aftermarket a Buy Signal?

Holley: A Long Drive Ahead

Truist Financial analyst Michael Swartz assigned a Buy rating to the stock today. The company's shares closed yesterday at $2.86. Swartz covers the...

Truist Financial Gives a Buy Rating to Holley (HLLY)

ALSN

HLLY

ITRN

MGDDY

Press Releases

APR and Dinan to Host Euro Enthusiasts at Opelika, Alabama Facility

Flowmaster Introduces Signature Series Premium Exhaust Line

Stilo Celebrates 25 Years of Safety and Racing Excellence

Penny Stocks

Small Cap

Holley Performance Brands to Release Third Quarter 2024 Results on November 8, 2024

Holley Performance Brands Expands Footprint at SEMA to Showcase Global Aftermarket Leadership

Holley Reports Third Quarter 2024 Results;
Execution Upon Strategic Initiatives Driving Growth in Key Areas of the Business
Completed Another Successful Event Season With Strong Enthusiast Engagement

MidOcean Partners Acquires Arnott Industries, a Leading Suspension Products Platform for the Auto Aftermarket

Holley to Attend Upcoming Investor Conferences

Holley Performance Brands' Enhanced Operational Performance and Recent Credit Upgrades Have Enabled an Amendment to the Revolving Credit Facility, Creating a Covenant-Lite Capital Structure

Holley Performance Brands to Showcase Safety and Racing Innovations at PRI 2024

Adient

Autoliv

Aptiv Holdings

American Axle & Manufacturing Holdings, Inc. Common Stock

American Axle & Mfg Hldgs

BorgWarner

Cooper-Standard Holdings Inc. Common Stock

Cooper-Standard Holdings

Dana

Dorman Prods

ECARX Holdings Inc. - Class A Ordinary shares

ECARX Holdings

Fox Factory Hldg

Gentex

Garrett Motion

Hesai Group - American Depositary Share, each ADS represents one Class B ordinary share

Comments

Holley

Interés en corto

Holley (NYSE:HLLY) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL